Literature DB >> 1254360

Mixed lymphocyte/tumor-cell interaction in a murine sarcoma virus (Moloney)-induced tumor system. Comparison between lymphoproliferation and lymphocyte cytotoxicity.

H Kirchner, M Glaser, H T Holden, R B Herberman.   

Abstract

Studies of the MLTI were performed in a primary MSV-induced tumor system. Reactivity against mitomycin-C-treated RBL-5 cells could be detected during a limited period at about 14 days after virus injection. The degree of reactivity of MSV 14 spleen cells was quite variable; stimulation indices ranged from 2.2 to 9.4. Activity in the MLTI appeared to a great extent to be dependent on T-lymphocytes. A relatively broad spectrum of specificity was demonstrated in experiments using additional stimulating cells besides RBL-5. The kinetics of the MLTI correlated well with the kinetics of the primary cytotoxic response in the CRA against RBL-5 cells. However, positive results in the in vivo and in vitro secondary cytotoxicity assays could be detected between 21 and 100 days after MSV injection when the MLTI was negative. Transplantation resistance against challenge with RBL-5 tumor cells also persists for a long time after MSV inoculation. Our data therefore indicate that the MLTI, in contrast to the secondary cytotoxicity assays, does not correlate well with the status of in vivo immunity.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1254360     DOI: 10.1002/ijc.2910170313

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Inhibitory effect of YC8 leukaemia cell line on in vitro lymphocyte reactivity.

Authors:  G Biasi; D Collavo; A Colombatti; L Chieco-Bianchi
Journal:  Br J Cancer       Date:  1977-05       Impact factor: 7.640

2.  Effect of recombinant human interleukin 2 on the growth of a BALB/c sarcoma induced by Moloney murine sarcoma virus.

Authors:  S Mitsunaga; H Kimura; Y Yamaguchi; A Mikata
Journal:  Jpn J Cancer Res       Date:  1988-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.